Stock GUARD GUARD THERAPEUTICS INTERNATIONAL AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:18:20 2024-04-29 am EDT 		5-day change 1st Jan Change
29.6 SEK -0.67% Intraday chart for Guard Therapeutics International AB +2.78% -17.32%
Apr. 15 Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER CI
Feb. 21 Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Business Summary

A1M Pharma AB is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Number of employees: 12

Managers

Managers TitleAgeSince
Tobias Larsson Agervald CEO
 Chief Executive Officer 48 18-11-30
Karin Botha DFI
 Director of Finance/CFO 51 20-09-13
Michael Reusch CTO
 Chief Tech/Sci/R&D Officer 64 21-12-31
Sara Thuresson CTO
 Chief Tech/Sci/R&D Officer 48 21-05-23
Torbjörn Larsson PRN
 Corporate Officer/Principal - 22-04-30

Members of the board

Members of the board TitleAgeSince
Johan Bygge CHM
 Chairman 68 21-04-30
Göran Forsberg BRD
 Director/Board Member 61 19-05-28
Fredrik Lehmann BRD
 Director/Board Member 48 22-11-30
Lars Höckenström BRD
 Director/Board Member 68 19-10-22
Johannes Hulthe BRD
 Director/Board Member 54 19-05-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 10,061,615 6,073,904 ( 60.37 %) 0 60.37 %

Shareholders

NameEquities%Valuation
Swedbank Robur Fonder AB
6.626 %
666,667 6.626 % 1 M kr
Strand Kapitalförvaltning AB
3.506 %
352,756 3.506 % 610 328 kr

Company contact information

Guard Therapeutics International AB

Nybrogatan 34 2nd Floor

114 39, Stockholm

+46 86 70 65 51

http://www.guardtherapeutics.com
address Guard Therapeutics International AB(GUARD)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GUARD THERAPEUTICS INTERNATIONAL AB Stock Guard Therapeutics International AB
-17.32% 27.35M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GUARD Stock
  4. Company Guard Therapeutics International AB